Vaccines Articles
Three top vaccine producers are making newer vaccines that not only protect against the newer sublineages of COVID-19, but that also protect against other respiratory viruses.
Although history has proven the success of vaccines in controlling the spread of diseases, emerging threats are concerning. However, hope is on the horizon with studies of newer vaccines.
Inborn errors of immunity (IEI) increase morbidity and mortality risks, particularly from respiratory tract infections. Hence, vaccination becomes pivotal for IEI patients.
Now that safe and effective RSV vaccines are finally available, more evidence of their direct health benefits in older Americans will be forthcoming. It is likely as well that FDA will eventually expand the marketing approvals of these vaccines to include adults under age 60 with chronic conditions demonstrated to importantly increase the risk of RSV-associated LRTD and hospitalization.
Researchers at the University of Wisconsin (UW) School of Medicine and Public Health are exploring the ideal vaccine booster strategy for immunosuppressed patients to protect those at higher risk of severe illness and complications from COVID-19 infection.
A new vaccine currently in development can effectively and affordably lower levels of “bad’ cholesterol in the body, a health problem that affects almost two in five adults in the U.S.
For decades, respiratory syncytial virus (RSV) has defied the best efforts of vaccine makers to bring it to heel, until now.
Politicization and polarization have made finding credible information online harder than ever.
Addressing patient misconceptions and uncertainty remains important to help get routine adult vaccinations back on schedule.
The effects of exposure to misinformation about vaccines has been exacerbated by the COVID-19 pandemic. And, misinformation continues to flourish with damaging consequences.
Research into targeted, effective vaccines for cancer remains ongoing.
The implementation of vaccine passports in response to the COVID-19 pandemic has raised arguments for and against them.
